Physician profile
Eugene Muchnik
NPI 1811286024
$62,871.40
in general payments reported to CMS, 2019-2025
36 companies · $21K in 2025
The $21K reported for 2025 was more than what 89% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $3,551 · 2023: $25K · 2024: $13K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $9,090 · Food and Beverage: $7,572 · Consulting Fee: $6,738 · Honoraria: $6,588 · Education: $38.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,081.50 |
| Travel and Lodging | $9,090.47 |
| Food and Beverage | $7,571.60 |
| Consulting Fee | $6,737.50 |
| Honoraria | $6,588.00 |
| Education | $38.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $30,687.84 | 2023-2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $15,448.43 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,672.55 | 2021-2025 | Opdivo, Krazati, Augtyro |
| Novartis Pharmaceuticals Corporation | $2,594.69 | 2022-2025 | Scemblix |
| Janssen Biotech, INC. | $2,020.84 | 2023-2025 | Imbruvica, Rybrevant, Talvey |
| Janssen Scientific Affairs, LLC | $1,837.03 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $1,318.75 | 2022-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $1,044.69 | 2022-2025 | Lynparza, Enhertu |
| Pfizer INC. | $344.74 | 2024-2025 | |
| Glaxosmithkline, LLC. | $316.89 | 2022-2025 | Ojjaara, Jemperli, Blenrep |
| Pharmacyclics LLC, An Abbvie Company | $274.18 | 2021-2022 | |
| Astellas Pharma US INC | $264.74 | 2024-2025 | Vyloy, Xtandi |
| Caris Mpi, INC. | $263.84 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $246.00 | 2023 | Zepzelca, Vyxeos |
| Genmab U.S., INC. | $220.04 | 2023-2024 | Epkinly, Tivdak |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $215.37 | 2023-2024 | Brukinsa |
| Menarini Silicon Biosystems, INC. | $162.60 | 2025 | |
| Abbvie INC. | $158.96 | 2025 | |
| Amgen INC. | $156.26 | 2024-2025 | Vectibix |
| Novocure INC. | $131.05 | 2023 | Optune Lua (Novottf-200t) |
| Adc Therapeutics America, INC. | $125.00 | 2025 | |
| Exelixis INC. | $125.00 | 2023 | Cabometyx |
| Springworks Therapeutics, INC. | $125.00 | 2025 | Gomekli |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Libtayo |
| Pharmacosmos Therapeutics INC. | $125.00 | 2025 | Cosela |
| Janssen Pharmaceuticals, INC | $124.74 | 2024 | Xarelto |
| Beone Medicines USA, INC. | $123.57 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $103.99 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Genentech USA, INC. | $97.94 | 2023 | Polivy, Lunsumio |
| Daiichi Sankyo INC. | $80.70 | 2025 | Datroway |
| Gilead Sciences, INC. | $76.31 | 2024-2025 | Trodelvy |
| Lilly USA, LLC | $74.34 | 2024 | Jaypirca |
| Sumitomo Pharma America, INC. | $62.61 | 2023 | Orgovyx |
| Adaptive Biotechnologies Corporation | $56.76 | 2023 | Clonoseq |
| Ge Healthcare | $34.19 | 2023 | |
| Array Biopharma INC | $31.76 | 2025 | Braftovi, Lorbrena, Mektovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Muchnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.